Two-dimensional (2D) in silico models for Absorption, Distribution, Metabolism, Excretion and Toxicity (ADME/T) in drug discovery

Current Topics in Medicinal Chemistry

Volumn 10, Issue 1, 2010, Pages 116-126

  Kharkar, Prashant S ^a  

^a WAYNE STATE UNIVERSITY   (United States)

Author keywords

ADME T modeling; ADME T predictions; ANN; Computational toxicology; QSAR; QSPR

Indexed keywords

ABC TRANSPORTER; ANTINEOPLASTIC AGENT; CARCINOGEN; CYTOCHROME P450; GLYCOPROTEIN P; NEW DRUG; POTASSIUM CHANNEL HERG; XENOBIOTIC AGENT;

ACCURACY; ARTIFICIAL NEURAL NETWORK; BLOOD BRAIN BARRIER; CARCINOGENICITY; CARDIOTOXICITY; CENTRAL NERVOUS SYSTEM; COMPUTER MODEL; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CYTOTOXICITY; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG FORMULATION; DRUG METABOLISM; DRUG PENETRATION; DRUG PROTEIN BINDING; DRUG RESEARCH; DRUG SCREENING; DRUG SOLUBILITY; ENZYME ACTIVITY; GENETIC ALGORITHM; HUMAN; INTESTINE ABSORPTION; LIPOPHILICITY; MEMBRANE TRANSPORT; MUTAGENICITY; NONHUMAN; PARTITION COEFFICIENT; PHYSICAL CHEMISTRY; PREDICTION; QUANTITATIVE STRUCTURE ACTIVITY RELATION; QUANTITATIVE STRUCTURE PROPERTY RELATION; REVIEW; TORSADE DES POINTES; TOXICITY TESTING;

COMPUTATIONAL BIOLOGY; DRUG DISCOVERY; DRUG TOXICITY; HUMANS; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 77949420079     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802610790232224     Document Type: Review

References (77)

1. Rawlins, M.D. Cutting the cost of drug development? Nat. Rev. Drug Discov., 2004, 3(4), 360-364.
2. a) Drews, J.; Ryser, S.T. An innovation deficit in the pharmaceutical industry. Drug Inf. J., 1996, 30(1), 97-108.
3. (b) Drews, J. Strategic trends in the drug industry. Drug Discov. Today, 2003, 8(9), 411-420.
4. a) Collins, F.S.; Patrinos, A.; Jordan, E.; Chakravarti, A.; Gesteland, R.; Walters, L. New goals for the U.S. Human Genome Project: 1998-2003. Science, 1998, 282(5389), 682-689.
5. (b) Müller, G. Medicinal chemistry of target family-directed masterkeys. Drug Discov. Today, 2003, 8(15), 681-691.
6. Kennedy, T. Managing the drug discovery/development interface. Drug Discov. Today, 1997, 2(10), 436-444.
7. a) Waterbeemd, H.v.d.; Gifford, E. ADMET in silico modeling: Towards prediction paradise? Nat. Rev. Drug Discov., 2003, 2(3), 192-204.
8. (b) Sarkar, A.; Kellogg, G.E. Hydrophobicity - shake flasks, protein folding and drug discovery. Curr. Top. Med. Chem., 2010, 1, 67-83.
9. Norinder, U.; Bergström, C.A.S. Prediction of ADMET properties. ChemMedChem, 2006, 1(9), 920-937.
10. Waterbeemd, H.v.d.; Testa B. In: Drug Bioavailability: Estimation of Solubility, Permeability, Absorption and Bioavailability; Waterbeemd, H.v.d., Testa, B., Eds.; WILEY-VCH Verlag GmbH & Co. KgaA: Weinheim, 2009; pp 1-6.
11. Wang, J.; Krudy, G.; Hou, T.; Zhang, W.; Holland, G.; Xu, X. Development of reliable aqueous solubility models and their application in druglike analysis. J. Chem. Inf. Model., 2007, 47(4), 1395-1404.
12. Lipinski, C.A.; Lombardo, F.; Dominy, B.W.; Feeney, P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev., 2001, 46(1-3), 3-26.
13. Jorgensen, W.L.; Duffy, E.M. Prediction of drug solubility from structure. Adv. Drug Deliv. Rev., 2002, 54(3), 355-366.
14. Jain, N.; Yalkowsky, S.H. Estimation of the aqueous solubility I: Application to organic nonelectrolytes. J. Pharm. Sci., 2001, 90(2), 234-252.
15. Palmer, D.S.; O'Boyle, N.M.; Glen, R.C.; Mitchell, J.B.O. Random forest models to predict aqueous solubility. J. Chem. Inf. Model., 2007, 47(1), 150-158.
16. a) Dearden, J.C. In silico prediction of aqueous solubility. Exp. Opin. Drug Discov., 2006, 1(1), 31-52.
17. (b) Delaney, J.S. Predicting aqueous solubility from structure. Drug Discov. Today, 2005, 10(4), 289-295.
18. (c) Johnson, S.R.; Zheng, W. Recent progress in the computational prediction of aqueous solubility and absorption. AAPS J., 2006, 8(1), E27-E40.
19. Nakao, K.; Fujikawa, M.; Shimizu, R.; Akamatsu, M. QSAR application for the prediction of compound permeability with in silico descriptors in practical use. J. Comput. Aided. Mol. Des., 2009, 23(5), 309-319.
20. Yamashita, F.; Hashida, M. In silico approaches for predicting ADME properties of drugs. Drug Metab. Pharmacokinet., 2004, 19(5), 327-338.
21. a) Garg, P.; Verma, J. In silico prediction of blood brain barrier permeability: An artificial neural network model. J. Chem. Inf. Model., 2006, 46(1), 289-297.
22. (b) Refsgaard, H.H.F.; Jensen, B.F.; Brockhoff, P.B.; Padkjr, S.B.; Guldbrandt, N.; Christensen, M.S. In silico prediction of membrane permeability from calculated molecular parameters. J. Med. Chem., 2005, 48(3), 805-811.
23. a) Zhao, Y.H.; Abraham, M.H.; Ibrahim, A.; Fish, P.V.; Cole, S.; Lewis, M.L.; de Groot, M.J.; Reynolds, D.P. J. Chem. Inf. Model., 2007, 47(1), 170-175.
24. (b) Konovalov, D.A.; Coomans, D.; Deconinck, E. Heyden, Y.V. Benchmarking of QSAR models for blood- brain barrier permeation. J. Chem. Inf. Model., 2007, 47(4), 1648-1656.
25. Lee, A.C.; Yu, J-y.; Crippen, G.M. pKa prediction of monoprotic small molecules the SMARTS way. J. Chem. Inf. Model., 2008, 48(10), 2042-2053.
26. Ghasemi, J.; Saaidpour, S; Brown, S.D. QSPR study for estimation of acidity constants of some aromatic acids derivatives using multiple linear regression (MLR) analysis. J. Mol. Struct.: THEOCHEM, 2007, 805(1-3) 27-32.
27. a values. A comparison of different theoretical approaches and a novel procedure. J. Mol. Struct.: THEOCHEM, 2004, 684(1-3), 121-128.
28. Lee, P.H.; Ayyampalayam, S.N.; Carreira, L.A.; Shalaeva, M.; Bhattachar, S.; Coselmon, R.; Poole, S.; Gifford, E.; Lombardo, F. In silico prediction of ionization constants of drugs. Mol. Pharm., 2007, 4(4), 498-512.
29. In, Y.; Chai, H.H.; No, K.T. A partition coefficient calculation method with the SFED model. J. Chem. Inf. Model., 2005, 45(2), 254-263.
30. Tetko, I.V.; Poda, G.I. Application of ALOGPS2.1 to predict logD distribution coefficient for Pfizer proprietary compounds. J. Med. Chem., 2004, 47(23), 5601-5604.
31. Bruneau, P.; McElroy, N.R. logD7.4 modeling using Bayesian regularized neural networks. Assessment and correction of the errors of prediction. J. Chem. Inf. Model., 2006, 46(3), 1379-1387.
32. Hou, T.J.; Wang, J.M.; Zhang, W.; Wang, W.; Xu, X. Recent advances in computational prediction of drug absorption and permeability in drug discovery. Curr. Med. Chem., 2006, 13(22), 2653-2667.
33. Yan, A.; Wang, Z.; Cai, Z. Prediction of human intestinal absorption by GA feature selection and support vector machine regression. Int. J. Mol. Sci., 2008, 9(10), 1961- 1976.
34. Hou, T.; Wang, J.; Li, Y. ADME evaluation in drug discovery. 8. The prediction of human intestinal absorption by a support vector machine. J. Chem. Inf. Model., 2007, 47(6), 2408-2415.
35. a) Hou, T.; Li, Y.; Zhang, W.; Wang, J. Recent developments of in silico predictions of intestinal absorption and oral bioavailability. Comb. Chem. High Throughput Screen., 2009, 12(5), 497-506.
36. (b) Kuentz, M. Prediction of drug absorption: different modeling approaches from discovery to clinical development. Exp. Rev. Clin. Pharmacol., 2009, 2(3), 217-219.
37. Tillement, J.-P.; Tremblay, D. Clinical Pharmacokinetic Criteria for Drug Research: The Why and How of Absorption, Distribution, Metabolism, Excretion, and Toxicity Research. In: ADME-Tox Approaches; Testa, B., Waterbeemd, H.v.D., Eds.; Comprehensive Medicinal Chemistry II, Taylor, J.B.; Triggle, D.J., Series Eds.: Elsevier: Oxford, 2007, 5, pp. 11-30.
38. Moda, T.L.; Montanari, C.A.; Andricopulo, A.D.; Hologram QSAR model for the prediction of human oral bioavailability. Bioorg. Med. Chem., 2007, 15(24), 7738-7745.
39. Hou, T.; Wang, J.; Zhang, W.; Xu, X. ADME evaluation in drug discovery. 6. Can oral bioavailability in humans be effectively predicted by simple molecular property-based rules? J. Chem. Inf. Model., 2007, 47(2), 460-463.
40. Shin, B.S.; Yoon, C.H.; Balthasar, J.P.; Choi, B.Y.; Hong, S.H.; Kim, H.J.; Lee, J. B.; Hwang, S.W.; Yoo, S.D Prediction of drug bioavailability in humans using immobilized artificial membrane phosphatidylcholine column chromatography and in vitro hepatic metabolic clearance. Biomed. Chromatogr. 2009, 23(7), 764-769.
41. Schwaighofer, A.; Schroeter, T.; Mika, S.; Hansen, K; Laak, A. t.; Lienau, P.; Reichel, A.; Heinrich, N.; Müller, K.-R. A probabilistic approach to classifying metabolic stability. J. Chem. Inf. Model., 2008, 48(4), 785-796.
42. Sakiyama, Y.; Yuki, H.; Moriya, T.; Hattori, K.; Suzuki, M.; Shimada, K.; Honma, T. Predicting human liver microsomal stability with machine learning techniques. J. Mol. Graph. Model., 2008, 26(6), 907-915.
43. Lee, P.H.; Cucurull-Sanchez, L.; Lu, J.; Du, Y.J. Development of in silico models for human liver microsomal stability. J. Comput-Aided Mol. Des., 2007, 21(12), 665-673.
44. Chang, C.; Duignana, D.B.; Johnson, K.D.; Lee, P.H.; Cowan, G.S.; Gifford, E.M.; Stankovic, C. J.; Lepsy, C.S.; Stoner, C.L. J. Pharm. Sci., 2009, 98(8), 2857-2867.
45. Gleeson, M.P. Plasma protein binding affinity and its relationship to molecular structure: An in silico analysis. J. Med. Chem., 2007, 50(1), 101-112.
46. Rodgers, S.L.; Davis, A.M.; Tomkinson, N.P.; Waterbeemd, H.v.d. QSAR modeling using automatically updating correction libraries: Application to a human plasma protein binding model. J. Chem. Inf. Model., 2007, 47(6), 2401-2407.
47. Gleeson, M.P.; Waters, N.J.; Paine, S.W.; Davis, A.M. In silico human and rat Vss quantitative structure-activity relationship models. J. Med. Chem., 2006, 49(6), 1953-1956.
48. Sui, X.; Sun, J.; Wu, X.; Li, H.; Liu, J.; He, Z. Predicting the volume of distribution of drugs in humans. Curr. Drug Metab., 2008, 9(6), 574-580.
49. Paixão, P.; Gouveia, L.F. Morais, J.A.G. Prediction of drug distribution in blood. Eur. J. Pharm. Sci., 2009, 36(4-5), 544-554.
50. a) de Graaf, C.; Vermeulen, N.P.; Feenstra, K.A. Cytochrome p450 in silico: An integrative modeling approach. J. Med. Chem., 2005, 48(8), 2725-2755.
51. (b) Crivori, P.; Poggesi, I. Computational approaches for predicting CYP related metabolism properties in the screening of new drugs. Eur. J. Med. Chem., 2006, 41(7), 795-808.
52. (c) Fox, T.; Kriegl, J.M. Machine learning techniques for in silico modeling of drug metabolism. Curr. Top. Med. Chem., 2006, 6(15), 1579-1591.
53. Terfloth, L.; Bienfait, B.; Gasteiger, J. Ligand-based models for the isoform specificity of cytochrome P450 3A4, 2D6, and 2C9 substrates. J. Chem. Inf. Model., 2007, 47(4), 1688- 1701.
54. Kriegl, J.M.; Eriksson, L.; Arnhold, T.; Beck, B.; Johansson, E.; Fox, T. Multivariate modeling of cytochrome P450 3A4 inhibition. Eur. J. Pharm. Sci., 2005, 24(5), 451-463.
55. Susnow, R.G.; Dixon, S.L. Use of robust classification techniques for the prediction of human cytochrome P450 2D6 inhibition. J. Chem. Inf. Model., 2003, 43(4), 1308-1315.
56. Burton, J.; Danloy, E.; Vercauteren, D.P. Fragment-based prediction of cytochromes P450 2D6 and 1A2 inhibition by recursive partitioning. SAR QSAR Environ. Res., 2009, 20(3-4), 185-205.
57. Jensen B.F.; Vind, C.; Padkjaer, S.B.; Brockhoff, P.B.; Refsgaard, H.H. In silico prediction of cytochrome P450 2D6 and 3A4 inhibition using Gaussian kernel weighted k-nearest neighbor and extended connectivity fingerprints, including structural fragment analysis of inhibitors versus noninhibitors. J. Med. Chem., 2007, 50(3), 501- 511.
58. Li, H.; Sun, J.; Sui, X.; Yan, Z.; Sun, Y.; Liu, X.; Wang, Y.; He, Z. Structure-based prediction of the nonspecific binding of drugs to hepatic microsomes. AAPS J., 2009, 11(2), 364-370.
59. Li, H.; Sun, J.; Sui, X.; Liu, J.; Yan, Z.; Liu, X.; Sun, Y. He, Z. First-principle, structure- based prediction of hepatic metabolic clearance values in human. Eur. J. Med. Chem., 2009, 44(4), 1600-1606.
60. Riley, R.J.; McGinnity, R.F.; Austin, R.P. A unified model for predicting human hepatic, metabolic clearance from in vitro intrinsic clearance data in hepatocytes and microsomes. Drug Metab. Dispos., 2005, 33(9), 1304-1311.
61. Szakács, G.; Váradi, A.; Özvegy-Lacza, C.; Sarkadi, B. The role of ABC transporters in drug absorption, distribution, metabolism, excretion and toxicity (ADME-Tox). Drug Discov. Today, 2008, 13(9-10), 379-393.
62. Gombar, V.K.; Polli, J.W.; Humphreys, J.E.; Wring, S.A.; Serabjit-Singh, C.S. Predicting P-glycoprotein substrates by a quantitative structure-activity relationship model. J. Pharm. Sci., 2004, 93(4), 957-968.
63. Demel, M.A.; Schwaha, R.; Krämer, O.; Ettmayer, P.; Haaksma, E.E.; Ecker, G.F. In silico prediction of substrate properties for ABC-multidrug transporters. Expert Opin. Drug Metab. Toxicol., 2008, 4(9),1167-1180.
64. th June 2009).
65. th June 2009).
66. Benfenati, E.; Benigni, R.; Demarini, D.M.; Helma, C.; Kirkland, D.; Martin, T.M.; Mazzatorta, P.; Ouédraogo-Arras, G.; Richard, A.M.; Schilter, B.; Schoonen, W.G.; Snyder, R.D.; Yang, C. Predictive models for carcinogenicity and mutagenicity: Frameworks, state-of-the-art, and perspectives. J. Environ. Sci. Health. C. Environ. Carcinog. Ecotoxicol. Rev., 2009, 27(2), 57-90.
67. Lee, A.C.; Shedden, K.; Rosania, G.R.; Crippen, G.M. Data mining the NCI60 to predict generalized cytotoxicity. J. Chem. Inf. Model., 2008, 48(7), 1379-1388.
68. Molnár, L.; Keserü, G.M.; Papp, Á; Lörincz, Z.; Ambrus, G.; Darvas, F. A neural network based classification scheme for cytotoxicity predictions: Validation on 30,000 compounds. Bioorg. Med. Chem. Lett., 2006, 16(4), 1037-1039.
69. Huang, R.; Wallqvist, A.; Covell, D.G. Assessment of in vitro and in vivo activities in the National Cancer Institute's anticancer screen with respect to chemical structure, target specificity, and mechanism of action. J. Med. Chem., 2006, 49(6), 1964-1979.
70. Roden, D.M. Drug-induced prolongation of the QT-interval. N. Engl. J. Med., 2004, 350(10), 1013-1022.
71. Nisius, B.; Göller, A.H. Similarity-based classifier using topomers to provide a knowledge base for hERG channel inhibition. J. Chem. Inf. Model., 2009, 49(2), 247- 256.
72. Thai, K.-M.; Ecker, G. F. A binary QSAR model for classification of hERG potassium channel blockers. Bioorg. Med. Chem., 2008, 16(7), 4107-4119.
73. Obrezanova, O.; Csányi, G.; Gola, J. M. R.; Segall, M. D. Gaussian processes: A method for automatic QSAR modeling of ADME properties. J. Chem. Inf. Model., 2007, 47(5), 1847-1857.
74. Yoshida, K.; Niwa, T. Quantitative structure-activity relationship studies on inhibition of hERG potassium channels. J. Chem. Inf. Model., 2006, 46(3), 1371-1378.
75. Muster, W.; Breidenbach, A.; Fischer, H.; Kirchner, S.; Müller, L.; Pähler, A. Computational toxicology in drug development. Drug Discov. Today, 2008, 13(7-8), 303-310.
76. Schultz, T.W.; Cronin, M.T.D. Pitfalls in QSAR. J. Mol. Struct.THEOCHEM 2003, 622(1-2), 39-51.
77. Yu, H.; Adedoyin, A. ADME-Tox in drug discovery: Integration of experimental and computational technologies. Drug Discov. Today, 2003, 8(18), 852-861.